Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Executive Officer | May 30, 2023 | May 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date May 30, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
After 2023-05-30 transaction · row 1
1 source rowRow 1 · 2023-05-30 · Purchase · Acquired 5,000 · Balance 5,000 F1: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.35. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.35. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2023 Filed May 30, 2023 22:24 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon stock | 5,000 | $4.31 | $21,550.00 |
DisclosureSEC source: 0001209191-23-032996 · doc4.xml · nonDerivative · entry 1 Jacot Stanley Jr · CIK 0001909085 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.35. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 04, 2023 Filed Apr 28, 2023 21:26 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001209191-23-026080 · doc4.xml · derivative · entry 1 Jacot Stanley Jr · CIK 0001909085 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,402 Underlying: Common Stock · 1,500 shares Expires 2033-04-04 F1 · derivative.exercise_date: The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 316,108 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-22-007154 · doc4.xml · derivative · entry 1 Jacot Stanley Jr · CIK 0001909085 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,108 Underlying: Common Stock · 316,108 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.